美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.82

+0.34801.01%

盤後：34.40-0.4200-1.21%17:31 EDT

成交量：1.41萬

成交額：48.93萬

市值：9,679.96萬

市盈率：- -

高：34.92

開：34.52

低：34.42

收：34.47

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：0.80

換手率：0.51%

股息：0.26

股息率：0.74%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

華蘭疫苗(301207.SZ)：新型流感病毒mRNA疫苗臨床試驗獲批目前國內尚無流感病毒mRNA疫苗產品獲批上市

華蘭疫苗(301207.SZ)：新型流感病毒mRNA疫苗臨床試驗獲批目前國內尚無流感病毒mRNA疫苗產品獲批上市

智飛生物：重組輪狀病毒亞單位疫苗獲臨床試驗批准

華蘭疫苗：新型流感病毒mRNA疫苗獲臨床試驗批准

諾華降膽固醇藥物遭遇挫折，令人們對新興心臟病藥物的期望蒙上陰影

轉型陣痛的昂利康：傳統業務增長失速，豪賭創新藥前景未明

甘李藥業(603087.SH)：GZC8072片Ⅰ期臨床試驗完成首例受試者給藥

一周兩度受挫！諾華(NVS.US)心臟病重磅藥III期折戟，股價大跌安進(AMGN.US)「躺槍」

我國首款AI輔助創新藥獲批上市，機構扎堆關注12只概念股

創新藥概念震盪反彈德展健康3天2板

港股概念追蹤 | 創新藥賽道持續升温 AI提效向臨床縱深推進(附概念股)

百利天恒：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告

证券日报网

國內首款AI輔助創新藥獲批上市！西湖大學聯合研發僅用時三年半

我國首款AI輔助創新藥獲批上市

創新藥三大指數上漲、ETF吸金，CXO及科研服務呈高景氣度

創新藥投資，優先佈局這些可把握的機會

证券市场周刊

復宏漢霖朱儁：未來所有製藥企業都是AI製藥企業，不存在不依賴AI的生物製藥企業

2026年國家醫保目錄現場談判競價與商保創新藥目錄價格協商在京開啓

康寧傑瑞生物製藥回購56,000股耗資492,430港元

中國中藥(00570)：1.1類中藥創新藥醒脾解鬱片獲批上市

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/IBBQ/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.82,"timestamp":1789416000000,"preClose":34.472,"halted":0,"volume":14092,"hourTrading":{"tag":"盘后","latestPrice":34.4,"preClose":34.82,"latestTime":"17:31 EDT","volume":27,"amount":933.299982,"timestamp":1789421478668,"change":-0.42,"changeRate":-0.012062,"amplitude":0.012062},"delay":0,"changeRate":0.01009514968670222,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"盤後交易","change":0.348,"latestTime":"09-14 18:20:44 EDT","open":34.52,"high":34.92,"low":34.42,"amount":489332.36950000003,"amplitude":0.014505,"askPrice":35.14,"askSize":8500,"bidPrice":34.39,"bidSize":8700,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":34.472,"sharesOutstanding":2520001,"nav":34.42313,"aum":95742920.24,"dividendRate":0.007412,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.4,"preClose":34.82,"latestTime":"17:31 EDT","volume":27,"amount":933.299982,"timestamp":1789421478668,"change":-0.42,"changeRate":-0.012062,"amplitude":0.012062},"volumeRatio":0.801383,"impliedVol":0.1149,"impliedVolPercentile":0.4861},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.801383,"shares":2780001,"dividePrice":0.2581,"high":34.92,"amplitude":0.014505,"preClose":34.472,"low":34.42,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.82,"committee":0.011628,"eps":0,"divideRate":0.007412,"volume":14092,"delay":0,"ttmEps":0,"open":34.52,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":36.05,"twentyDayClose":33.8122,"sixtyDayClose":29.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665550318","title":"華蘭疫苗(301207.SZ)：新型流感病毒mRNA疫苗臨床試驗獲批 目前國內尚無流感病毒mRNA疫苗產品獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2665550318","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665550318?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:42","pubTimestamp":1788770526,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华兰疫苗 发布公告，公司于近日收到国家药品监督管理局核准签发的关于新型流感病毒mRNA疫苗的《药物临床试验批准通知书》。公司研发的新型流感病毒mRNA疫苗采用mRNA技术路线，通过递送编码流感病毒相关抗原的mRNA，在体内表达相应抗原并诱导机体产生免疫应答。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492774.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301207","MRNY","IPOS","PSYK","BMED","IBBJ","MRNX","MDTX","IBBQ","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665318561","title":"華蘭疫苗(301207.SZ)：新型流感病毒mRNA疫苗臨床試驗獲批 目前國內尚無流感病毒mRNA疫苗產品獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2665318561","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665318561?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:42","pubTimestamp":1788770526,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","IBBQ","IBBJ","MRNY","PSYK","BMED","IPOS","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665188143","title":"智飛生物：重組輪狀病毒亞單位疫苗獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665188143","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665188143?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:38","pubTimestamp":1788770300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","PSYK","IBBQ","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665390071","title":"華蘭疫苗：新型流感病毒mRNA疫苗獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665390071","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665390071?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:37","pubTimestamp":1788770253,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MRNY","PSYK","MDTX","IBBQ","IBBJ","MRNX","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665699390","title":"諾華降膽固醇藥物遭遇挫折，令人們對新興心臟病藥物的期望蒙上陰影","url":"https://stock-news.laohu8.com/highlight/detail?id=2665699390","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665699390?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:11","pubTimestamp":1788768711,"startTime":"0","endTime":"0","summary":"罕见病药物备受期待市场关注点现将转向第四季度其RNA疗法del-desiran的后期临床试验结果。该药物用于治疗一种罕见肌肉疾病，系通过收购Avidity公司获得。诺华公司另一款抗炎药物雷米布替尼针对一种名为脓疱性汗腺炎的皮肤病所开展的研究数据，预计也将于今年公布。该药物上周在多发性硬化症患者的临床试验中取得了成功。这两家竞争对手的药物均在与佩拉卡森类似的临床试验中进行测试，这些试验依赖于确诊的心脏相关事件，且没有明确的结束日期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nL4T44Z0IF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2491049909.HKD","LU1988902786.USD","MEDX","THNR","LLY","AGNG","IBB","WDNA","LLII","LU2324357040.USD","IXJ","FHLC","MHIP","BK4581","LU1551013425.SGD","IBBQ","ELIL","IYH","BK4588","LLYZ","BIB","PPH","OZEM","RXL","VHT","PBE","ELIS","AMGN","IHE","NAMS","TBXU","BBH","FTXH","LLYX","LU2746668974.SGD","MEDI","CURE","CANC","GDOC","XLV","LU0096364046.USD","IE00BK4W5L77.USD","TMED","TRUH","LU0456855351.SGD","PJP","JDOC","HRTS","SLN","ILDR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665904373","title":"轉型陣痛的昂利康：傳統業務增長失速，豪賭創新藥前景未明","url":"https://stock-news.laohu8.com/highlight/detail?id=2665904373","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665904373?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:08","pubTimestamp":1788768480,"startTime":"0","endTime":"0","summary":"证券之星注意到，2026年上半年，昂利康营收、净利双双下滑逾10%，传统业务中原料药收入持续缩水，特色中间体规模更是“腰斩”，成为主要拖累。传统业务增长失速、创新业务远水难解，昂利康能否在多重压力中突围，仍有待时间检验。昂利康提示风险称，肿瘤创新药产品各阶段的成功率相对于其他创新药低，风险较高，不确定性较大。昂利康如何在传统业务与创新药漫长培育期之间找到平衡，才是市场关注的焦点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-09-07/doc-iniqyvry5536300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","MEDX","IBBQ","BK0239","159992","LNGR","BK1161","BK1574","002940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665397088","title":"甘李藥業(603087.SH)：GZC8072片Ⅰ期臨床試驗完成首例受試者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2665397088","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665397088?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 15:52","pubTimestamp":1788767548,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业 发布公告，公司全资子公司甘李药业山东有限公司自主研发的GZC8072片正在中国开展Ⅰ期临床试验，于近日成功完成首例受试者给药。GZC8072片是新一代偏向型超长效多肽口服周制剂，正在开展用于肥胖或超重、2型糖尿病的适应症的临床试验。据悉，该产品于2026年8月、9月分别获得国家药品监督管理局下发的适应症为肥胖或超重、2型糖尿病的《药品临床试验批准通知书》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK0239","MDTX","603087","PSYK","IBBJ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665392789","title":"一周兩度受挫！諾華(NVS.US)心臟病重磅藥III期折戟，股價大跌安進(AMGN.US)「躺槍」","url":"https://stock-news.laohu8.com/highlight/detail?id=2665392789","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665392789?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 15:15","pubTimestamp":1788765302,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞士制药巨头诺华制药再遭临床试验打击——一周之内，该公司第二项重磅候选药物在后期研究中折戟。此次失利的是其潜在明星心脏病药物pelacarsen。受此消息影响，诺华在美上市股票上周五常规交易结束后一度下跌逾7%。开发类似心脏药物的安进股价上周五盘后也下挫近6%。诺华正寄望于一系列新药来支撑增长，以应对旗下多款重磅产品专利即将到期的压力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BIB","LU0058720904.USD","IE0009355771.USD","BK4533","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4007","LU1057294990.SGD","MEDX","LU2242652126.USD","SG9999001440.SGD","BK4599","LU0070302665.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU0208291251.USD","LU0889565916.HKD","LU0211331839.USD","LU2089984988.USD","LU1061106388.HKD","AMGN","BK4532","BK4139","LU2242646821.SGD","BK4585","LU2112291526.USD","LU0320765489.SGD","TBXU","IE00B2B36J28.USD","LU0122379950.USD","BK4566","IE00B4R5TH58.HKD","LU1571399168.USD","LU2468319806.SGD","PBE","LU0320765992.SGD","IBBQ","BK4588","LU0289739699.SGD","LU0868494617.USD","NVS","PPH","PJP","LU1023059063.AUD","BK4581","IBB","BK4534","BK4578","IE0002141913.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665628399","title":"我國首款AI輔助創新藥獲批上市，機構扎堆關注12只概念股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665628399","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665628399?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 12:35","pubTimestamp":1788755705,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","QTOC","IPOS","LNGR","IBBQ","CHAT","AGIX","AIPO","ARTY","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665895395","title":"創新藥概念震盪反彈 德展健康3天2板","url":"https://stock-news.laohu8.com/highlight/detail?id=2665895395","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665895395?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 10:15","pubTimestamp":1788747304,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665836774","title":"港股概念追蹤 | 創新藥賽道持續升温 AI提效向臨床縱深推進(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665836774","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665836774?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 06:53","pubTimestamp":1788735233,"startTime":"0","endTime":"0","summary":"西湖大学生命科学学院教授黄晶表示，AI辅助新药研发已不止于概念，而真正可以支撑原创药物从发现走向临床，直至上市。艾普司韦是西湖大学首款完全自主研发的1类创新药，用于成人轻型、中型新型冠状病毒感染的治疗。中国AI制药市场规模2025年已突破6亿元。从经营数据来看，AI相关业务正成为部分企业订单和收入增长的重要驱动力；与此同时，下游药企也在积极拥抱AI，研发提效成果逐步显现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AGIX","BK1574","BK4588","ARTY","BK1617","02196","BK1515","IBBQ","CHAT","BK4585","BK1191","BK1593","06978","159992","BK1161","02228","AIPO","03696","MEDX","BK1141","KCAI","VTHR","QTOC","LNGR","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665709364","title":"百利天恒：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665709364","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665709364?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 18:31","pubTimestamp":1788690660,"startTime":"0","endTime":"0","summary":"证券日报网讯9月6日，百利天恒发布公告称，公司计划于2026年9月16日15：00-17：00参加科创板2026年半年度创新药行业集体业绩说明会，就投资者关心的问题进行交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-06/doc-iniqwwyu6754784.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-06/doc-iniqwwyu6754784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["KSTR","688506","BK0239","06978","IBBQ","BK1161","MEDX","91194","159992","BK1574","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665403361","title":"國內首款AI輔助創新藥獲批上市！西湖大學聯合研發 僅用時三年半","url":"https://stock-news.laohu8.com/highlight/detail?id=2665403361","media":"快科技","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665403361?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 15:30","pubTimestamp":1788679839,"startTime":"0","endTime":"0","summary":"快科技9月6日消息，据西湖大学微信公众号消息，近期，由西湖大学、西湖实验室、西湖制药联合研发的创新药——盐酸伊司特韦片 正式获得国家药品监督管理局附条件批准上市。据悉，它是国内首款凭借AI辅助研发而获批上市的原创药——从源头发现到完成临床试验，仅用时三年半。这也是西湖大学首款完全自主研发的1类创新药，用于成人轻型、中型新型冠状病毒感染的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8wCSabf9QIo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["AGIX","AIPO","BK1574","IPOS","QTOC","MEDX","BK1161","CHAT","159992","VTHR","06978","LNGR","IBBQ","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665361592","title":"我國首款AI輔助創新藥獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2665361592","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665361592?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 15:04","pubTimestamp":1788678281,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS","QTOC","AIPO","VTHR","LNGR","ARTY","CHAT","AGIX","IBBQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665369630","title":"創新藥三大指數上漲、ETF吸金，CXO及科研服務呈高景氣度","url":"https://stock-news.laohu8.com/highlight/detail?id=2665369630","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665369630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 09:57","pubTimestamp":1788659820,"startTime":"0","endTime":"0","summary":"H股创新药指数2026上半年收入同比增长17.91%、归母净利润同比增长60.94%、扣非归母净利润同比增长30.73%。银河证券分析称，上半年行业利润增长显著快于收入，主要系创新药商业化收入及对外授权收入增加，高毛利业务占比大幅提升，同时CXO和科研服务呈高景气度，订单增长驱动前期产能建设和人员储备充分利用，摊薄固定成本并推动利润增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqvzvc0193188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MEDX","BK4585","BK4550","BK1574","IBBQ","LNGR","06978","FDN","WX","BK1161","CXO","BK4588","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665538368","title":"創新藥投資，優先佈局這些可把握的機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2665538368","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665538368?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 14:51","pubTimestamp":1788591110,"startTime":"0","endTime":"0","summary":"当AI行情阶段性休整、市场四处寻找下一条主线之时，创新药板块悄然走出一轮反弹行情。Wind数据显示，2026年6月9日至9月2日，恒生沪深港创新药50指数涨幅达到33.08%，CXO指数涨幅46.07%。但赛道本身波动性也极强。2025年前三季度，部分创新药指数最高涨幅超100%，随后自去年10月开启长达8个月的深度调整，截至2026年5月底，板块最大回撤超过30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053866007987.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053866007987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06978","159992","IBBQ","LNGR","BK1574","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665936888","title":"復宏漢霖朱儁：未來所有製藥企業都是AI製藥企業，不存在不依賴AI的生物製藥企業","url":"https://stock-news.laohu8.com/highlight/detail?id=2665936888","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665936888?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 14:04","pubTimestamp":1788588240,"startTime":"0","endTime":"0","summary":"朱俊坦言，尽管近年来国家批准的创新药数量已领先全球，但临床疗效的提升依然艰难。他强调，如果AI不能进一步赋能，生物医药产业将继续处于原始状态。未来，所有的制药企业都必须是AI制药企业，不存在不依赖AI的生物制药企业。朱俊总认为，在全球变局下，只要企业能够用好AI、抓住精准人群并解决真实的临床痛点，即使十个机会中只能抓住一个，也足以支撑企业的长远发展。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-09-05/doc-iniquccs3668085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BBP","HK0000165453.HKD","AGIX","MRNX","BK1191","HK0000320264.USD","AIPO","03069","HK0000306685.HKD","02696","MRNY","BK1574","01477","VTHR","HK0000320223.HKD","ARTY","QTOC","HK0000306701.USD","BK1161","CHAT","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665352256","title":"2026年國家醫保目錄現場談判競價與商保創新藥目錄價格協商在京開啓","url":"https://stock-news.laohu8.com/highlight/detail?id=2665352256","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665352256?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 08:12","pubTimestamp":1788567172,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664337721","title":"康寧傑瑞生物製藥回購56,000股 耗資492,430港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664337721","media":"财闻","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664337721?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 20:53","pubTimestamp":1788526380,"startTime":"0","endTime":"0","summary":"9月4日，康宁杰瑞生物制药于2026年9月4日在香港联交所回购56,000股普通股，每股回购价格最高HKD8.8、最低HKD8.75，付出价格总额HKD492,430。回购股份拟持作库存股份，拟注销数目为0。回购后，已发行股份数目由968,056,697股减至968,000,697股，库存股份数目由6,325,000股增至6,381,000股，已发行股份总数维持974,381,697股。此次回购依据2026年6月12日获通过的回购授权进行，该授权可回购股份总数为96,850,669股。回购后暂止期截至2026年10月4日。呈交者为执行董事徐霆。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-04/doc-iniqsrak4001786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","03069","CNAV","MRNY","BBP","EWH","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664334496","title":"中國中藥(00570)：1.1類中藥創新藥醒脾解鬱片獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2664334496","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664334496?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 20:50","pubTimestamp":1788526251,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国中药(00570)发布公告，有关国家药监局受理集团的附属公司国药集团同济堂（贵州）制药有限公司（同济堂制药）的1.1类中药创新药郁枢达片注册上市申请。经国家药监局完成技术审评、现场核查、抽样检验等一系列工作程序，同济堂制药申报的1.1类中药创新药醒脾解郁片（即先前公告所称“郁枢达片”，为该药品获国家药监局核准的规范通用名称）已获得批准上市，药品上市许可持有人为同济堂制药。醒脾解郁片具有醒脾化湿、理气解郁的功效，用于轻、中度抑郁症，症状为情绪郁闷、低落，表情淡漠、倦怠乏力、失眠多梦、少气懒言、食少纳呆，头重肢困、 口中黏腻、面色晦暗，舌淡苔白腻或灰腻、脉滑或弦。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","IBBQ","00570","BK1606","BK1515","BK1574","BK1191","06978","159992","BK1161","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":7,"totalSize":201,"code":"91000000","status":"200"}]}}